Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Axogen Inc.

In a report released today, Caitlin Roberts from Canaccord Genuity reiterated a Buy rating on AxoGen, with a price target of $50.00. According to T...

Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (NAGE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), AxoGen (AXGN) and Wave Li...

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), AxoGen (AXGN)

In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on AxoGen, with a price target of $50.00. Takkinen covers the H...

Current Quarter	$-0.01	Next Quarter	$0.02
Current Year	$-0.3	Next Year	$0.31
QoQ Growth	+300.0%	YoY Growth	+203.3%
3Y EPS CAGR	+29.3%	Target Price	$50.00
Consensus	Buy	Upside	+20.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXGN	$41.45	+1.34%	688.65K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXGN	$41.45	+1.3%	688.65K
3
4
5
6

AXGN

AXGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Axogen Inc. Data in Excel

Get Axogen Inc. Data in Excel